Results 161 to 170 of about 2,252,807 (303)

Modeling neonatal immune response to B. pertussis identifies early B cell activation and differentiation. [PDF]

PLoS Pathog
Matczak S, Sadi M, Leroux P, Labé P, Bouchez V, Schmutz S, Libri V, Seffer V, Novault S, Volant S, Brisse S, Hasan M, Duffy D, Tonnerre P, Toubiana J.   +14 more
europepmc   +1 more source

B-Cell Activation [PDF]

, 2020
openaire   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Corrigendum: TACI Isoforms Regulate Ligand Binding and Receptor Function

Frontiers in Immunology, 2019
Yolanda Garcia-Carmona, Adrian T. Ting, Lin Radigan, Sai Krishna Athuluri Divakar, Jose Chavez, Eric Meffre, Andrea Cerutti, Andrea Cerutti, Andrea Cerutti, Charlotte Cunningham-Rundles, Charlotte Cunningham-Rundles   +10 more
doaj   +1 more source

Altered B cell activation contributes to the immunopathogenesis of childhood arthritis-associated uveitis. [PDF]

Nat Commun
Jebson BR, Ingledow B, Alexiou V, Kubiak J, Jenkins P, Meng Y, Kartawinata M, Restuadi R, Lin WY, Wallace C, Chu CJ, Solebo AL, Wedderburn LR, Rosser EC, CLUSTER consortium.   +14 more
europepmc   +1 more source

CD22L Conjugation to Insulin Attenuates Insulin-Specific B Cell Activation. [PDF]

Bioconjug Chem, 2023
Apley KD, Griffith AS, Downes GM, Ross P, Farrell MP, Kendall P, Berkland CJ.   +6 more
europepmc   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Cytotoxic T-cell deficiency and sustained B-cell activation in serofast syphilis: a prospective observational study. [PDF]

Front Immunol
Kaminiów K, Kiołbasa M, Napiórkowska-Baran K, Pastuszczak M.   +3 more
europepmc   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

Curbing Autoimmunity: A New Fab Fragment Targeting CD40-CD40L Halts B-Cell Activation and Differentiation. [PDF]

Eur J Immunol
Pedersen K, Green K, Kristoffersen EL, Schinkel T, Hansen AG, Palarasah Y, Rovsing AB, Andersen ES, Valero J, Civit L, Laursen NS, Troldborg A, Degn SE, Thiel S.   +13 more
europepmc   +1 more source